Brit. med. J., 1968, 2, [147] [148] [149] There is as yet no real information about the prevalence of aphthous ulceration in the general population. In a sample of 1,500 consecutive hospital outpatients it was estimated that one out of every five at some period of their life suffered from this form of mouth ulceration (Sircus et al., 1957) . In a survey of a professional school population carried out by Ship et al. (1960) a prevalence of about 54% was recorded, and in a further study of a student body the prevalence was 66% (Ship et al., 1967) . The cause of aphthous ulceration is unknown, so that methods of treatment have been entirely empirical. It has been.
suggested that benefit to the patient may follow the use of antibiotics (Zegarelli et al., 1952 ; Sircus et al., 1957) , viral vaccines (Woodburne, 1941) , gammaglobulin (Fraser-Moodie, 1960) , quinoline derivatives (Natarajan, 1964) , mucosal protectants (Barile and Grayskowski, 1963) , corticosteroids (Truelove and Morris-Owen, 1958; Sircus, 1959; Cooke and Armitage, 1960) , oestrogens (Bishop et al., 1967) , and antiseptic, anaesthetic, or analgesic preparations too numerous to recount.
The disease has a natural rhythm of exacerbation and spontaneous remission which complicates any assessment of the true value of treatment (Sircus, 1959) , and in general it is difficult to decide to what extent the benefit which has been claimed to follow the use of these preparations exists in fact, as against being the subjective impressions of the clinicians who prescribed them or of the patients who received them.
On the basis of such information as is available from controlled studies it seems that the most promising approach to treatment lies in the administration of a small dose of corticosteroids. After a controlled trial with 2.5-mg. tablets of hydrocortisone hemisuccinate (Corlan pellets), Cooke and Armitage (1960) stated: " When considering all the patients together the degree of ulceration was reduced by about 50%," during the period of the trial, " and the reduction could often be maintained for three to six months" thereafter.
Pilot Study
A double-blind pilot study was designed in Edinburgh to investigate the effects of triamcinolone acetonide (Adcortyl-A in Orabase) and hydroxyquinoline on a group of 17 patients with severe continuous aphthous ulceration, no patient having been free of ulceration for more than seven days during the previous six months. Orabase (an ointment containing carboxymethylcellulose), which is the vehicle used for the administration of the proprietary preparation of triamcinolone, was included to serve as control for this preparation. (Table I ) is a measure of the incidence of ulceration within the trial period. The mean number of new ulcers occurring in relation to each treatment was remarkably consistent, and the analysis of variance confirms that the differences between the treatments are not significant. Similarly, the total number of new ulcer days is an index of the duration of new ulcers occurring within the trial period (Table  II) . The mean duration of ulcers ranged from 60 to 73 days, and analysis of variance showed that differences between the treatments are not significant. These findings were independent of the drug-placebo order. With respect to steroids the results indicated that triamcinolone given over a period of four weeks in the dose range used was unlikely to be effective against aphthous ulceration of the degree of severity selected for the trial. Trial Design At a meeting of the consultants in charge of four centres in different parts of the country it was decided to co-operate in a therapeutic trial to overcome the problem of patient fall-out and the difficulty of assessing therapeutic effects in cyclic disorders.
The treatments to be investigated were local application of Orabase and triamcinolone as in the pilot study, systemic betamethasone disodium phosphate (Beta-Corlan), the tablets being swallowed ; local betamethasone, the tablets being allowed to dissolve-slowly in the mouth; and Biobase (carbenoxolone sodium in a bland adhesive vehicle). Each patient followed a sequence of two drugs over a four-month period, with a blank month intervening and a blank month following. The dosages used were: triamcinolone and Orabase applied to existing lesions four times daily to a calculated range of dosage of 0.24 to 1 mg.; Orabase applied to existing lesions four times a day; betamethasone, one 0.1-mg. tablet allowed to dissolve slowly in the mouth four times a day whether lesions were present or not; one betamethasone 0.1-mg. tablet swallowed four times a day whether the lesions were present or not; and carbenoxolone applied to existing lesions four times a day. The amount of triamcinolone used was dependent on the frequency and duration of the ulceration. The dosage of betamethasone was constant whether the patient had ulcers or not, and can be regarded as a maintenance dose of 0.4 mg./day, over 28 days, given by different routes of absorption.
Early in the trial two of the consultants became concerned with the potential risks of the administration of steroids to patients and withdrew, though search of the literature revealed no direct evidence that with a total dose which ranged from 0.24 to 1 mg. of triamcinolone or 0.4 mg. of betamethasone daily such risks existed. The units in Edinburgh and Liverpool elected to continue the trial until it was just possible to reach a statistically valid conclusion, but arrangements were made to investigate the effect on adrenocortical function of 0.4 me. of betamethasone daily allowed to dissolve in the mouth. When it became clear that this dosage of betamethasone could have a greater systemic effect than had been previously appreciated, by general agreement the trial was stopped. At this stage 80 patients had been accepted for treatment in Liverpool and Edinburgh, 31 had completely fulfilled the conditions of the trial, and one further patient had completed a full comparison for carbenoxolone alone. This patient has been included in the analysis. The ulceration in all the 31 patients fell within group 1 and group 3 aphthae (Kramer, 1965) , with the exception of one patient who also had infrequent vaginal ulceration. The distribution of these patients with regard to sex and severity of ulceration in the six months before the trial is shown in Table III . With regard to duration of symptoms, more than half the patients had had the disease for five years or more, and one-third for 10 years or more. Overall there is no statistically demonstrable evidence that any of the treatments altered either the incidence or the duration of ulceration during the period of the trial. These findings are independent of the treatment/control order. 
Results
At the time the trial was stopped the patients were fairly evenly distributed with regard to the treatments (Table IV) . The average number of new ulcers per month is a measure of the incidence of ulceration in the month of treatment as against the control month. The figures are remarkably consistent, the differences between the treatment and control months are small, and none approach statistical significance (P>0.05). ulceration after the use of betamethasone of 28 %, compared with the figure of 50% reduction with hydrocortisone pellets reported by Cooke and Armitage. It is not possible to make a proper statistical comparison from such extended figures, but it is of interest that the change, though insignificant statistically, is in the same direction. Since the drug doses are equivalent, one explanation of the difference between the two sets of results may lie in the different duration of treatment-four weeks as against eight weeks. It is possible that the effect may not show until the patient has been taking the drug for a minimum period in excess of four weeks.
A further explanation is suggested by a Bartlett test of homogeneity of variance which was significant over the five treatments (P<O.O1). The largest variance was associated with the use of betamethasone allowed to dissolve in the mouth. This suggests the possibility that there may be " interaction " between effectiveness of the steroid and type of patient.
The question arises whether the evidence of benefit is sufficiently clear-cut to justify the prolonged use of steroids for treatment of aphthous ulceration and to compensate for any risk to the patient which may exist at the suggested level of dosage. The estimated minimum dose producing marked adrenal suppression is held to be of the order of 50 mg. of hydrocortisone or equivalent daily (Lehner, 1967) Betamethasone 17-valerate may be safer in that 4 mg./day did not suppress adrenal function in a colitis trial (Friedman et al., 1967 (Scoggins and Kliman, 1965; Jasani et al., 1967; Otaki, 1967) .
Summary
There is no evidence of alteration of incidence or duration of aphthous ulceration following the use of triamcinolone acetonide (Adcortyl-A in Orabase), Orabase, hydroxyquinoline, carbenoxolone sodium (Biobase), or betamethasone disodium phosphate (Beta-Corlan), for a period of four weeks.
Depression of the hypothalamo-pituitary-adrenal axis can follow sublingual absorption of 0.4 mg. of betamethasone daily.
There is a need for study of morbidity and mortality arising in patient populations on long-term treatment with small doses of corticosteroids.
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